Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Seasonique tablet

Canada Type I Ongoing · initiated 2025-06-06

Packaging. Do not stop taking Seasonique. Do not skip taking any blue–greenCheck your package. If your package contains an extra row of yellow pills in Tray 1 a…

Seasonale tablet

Canada Type I Ongoing · initiated 2025-06-05

Packaging. Do not stop taking Seasonale. Do not skip taking any active (pink) pills until the very last row of tray 3 (which is the placebo [white] pills).Check…

Amneal Pharmaceuticals, LLC

US Class I Ongoing · initiated 2025-06-02

Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC

US Class II Ongoing · initiated 2025-06-02

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Sanis-Moxifloxacin solution

Canada Type II Ongoing · initiated 2025-06-02

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-05-30

Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage …

Advanced Pharmaceutical Technology, Inc.

US Class II Ongoing · initiated 2025-05-30

Marketed Without an Approved NDA/ANDA

JAMP-RISPERIDONE

Canada Type III Ongoing · initiated 2025-05-30

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Macleods Pharmaceuticals Ltd

US Class III Ongoing · initiated 2025-05-29

Presence of a foreign substance: black hair found embedded in tablet.

Eugia US LLC

US Class II Ongoing · initiated 2025-05-29

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Apotex Corp.

US Class II Ongoing · initiated 2025-05-28

Defective Container: This recall is being initiated due to a leaking unit stored horizontally.

Apotex Corp.

US Class II Ongoing · initiated 2025-05-28

Lack of Assurance of Sterility

Apotex Corp.

US Class II Ongoing · initiated 2025-05-28

Lack of Assurance of Sterility

Pfizer Inc.

US Class II Ongoing · initiated 2025-05-28

Discoloration; discolored solution from cracked vials

Apotex Corp.

US Class II Ongoing · initiated 2025-05-28

Lack of Assurance of Sterility

JAMP-ASA 81MG EC

Canada Type II Ongoing · initiated 2025-05-28

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Torrent Pharma Inc.

US Class II Completed · initiated 2025-05-27

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Torrent Pharma Inc.

US Class II Completed · initiated 2025-05-27

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Fresenius Medical Care Holdings, Inc.

US Class II Ongoing · initiated 2025-05-27

Lack of Assurance of Sterility

Sivem ezetimibe 10 mg tablets

Canada Type I Ongoing · initiated 2025-05-27

Product safety. Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets.Sivem ezetimibe 10 mg is a white oblong tablet, with “93" …